The Phoenix Issues
Origins of the Original “Phoenix List”: “Upon the creation of the Federal Circuit [in 1982], Chief Judge Howard Thomas Markey created a ‘Phoenix List’ to fulfill what he saw as the “duty of [the new court] of clarify the law of patents itself [which] will require the resolution of numerous apparent conflicts [amongst the circuits] lurking in past decisions and decisional approaches of various courts.” William C. Rooklidge & Matthew F. Weil, En Banc Review, Horror Pleni, and the Resolution of Patent Law Conflicts, 40 Santa Clara L. Rev. 787, 802 (2000)(citing Howard T. Markey, The Phoenix Court, 10 Am. Pat. L. Ass’n Q.J. 227, 232 (1982)). Following Chief Judge Markey’s lead, The Naples Roundtable identifies current issues in need of clarification. These issues focus our attention, foster our discussion, and inspire us to work toward making the U.S. patent system an “engine of innovation.”
CURRENT PHOENIX ISSUES
Phoenix Issue I. Has the value of US patents decreased over the last 10 years and are there ways to strengthen and improve the Patent System? What can and should be done to improve the process? Are the pending proposals in Congress needed and if so will they help? Do some of the AIA provisions need to be scrapped or modified? A recent Federal Register notice by the PTO sets forth proposed for the first time in the history of our patent system, a practitioner fee and CLE requirements; should these be imposed?
Phoenix Issue II. Is the patent litigation being abusively utilized today or have unjustified actions been significantly curbed? Have IPRs, changes in venue selection and the more frequent award of attorneys’ fees helped? Are changes need in the IPR process and what changes are in the works; will such changes help? What is the impact of recent and proposed changes — considering all claims and proposed ground of invalidity and claim interpretation standards?
Phoenix Issue III. Is there a problem with Section 101 decisions and will there likely be any legislative fix? If not, then what if anything can be done? Is it easier in foreign countries to obtain patents on subject matter considered abstract and unpatentable in the US? What if any impact is this having on innovation in the US?
Phoenix Issue IV. Should deference (under Chevron) be given to the PTAB decisions and to what extent? Should any change in deference also impact ITC decisions? What is the level of review that should be done by the Federal Circuit on various issues (e.g. claim construction and assignor estoppel)?
Phoenix Issue V. Does the current law of damages and injunctions adequate in protecting rights of patent holders? What is the impact in investing in and promoting innovation? How does the handling of damage and injunction issues in the US compare to countries in Europe and Asia?
Phoenix Issue VI. Is there a current conflict between implementation of the patent laws and antitrust laws?
Phoenix Issue VII. To what extent is the patent system well-served by the extra-territorial enforcement of competition and intellectual property laws?
Phoenix Issue VIII. Is there a need to substantially revise the rules to bring the content of patent applications in line with modern precedent, new types of technologies (e.g. AI) and to impose reasonable limits on the size of specifications and the number of claims that should be allowed in an application? For example, should the requirement for a section entitled “Background of the Invention” be replaced by sections covering “The Scope and Content of the Prior Art’ and “The Level of Ordinary Skill in the Art?” Should the USPTO resurrect its once prevalent use of “undue multiplicity” rejections? Should the Office require applicants to state whether they intend for the preamble of their claims to be construed as a limitation on the scope of the claims? Should the Office require applicants to state whether they intend for their claims to be interpreted as means-plus-function claims?
Phoenix Issue IX. To protect against willful infringement allegations after Halo, should parties obtain opinions from counsel and what waiver issues arrive?
Phoenix Issue X. Understanding the conflict of positions in the SEP/FRAND issues both in the US and Internationally and can the conflicts be resolved?
HISTORICAL PHOENIX ISSUES
Phoenix Issue I. Has the AIA strengthened the patent system and decreased the cost of removing invalid patents? Has AIA gone far enough? What can and should be done to improve the process?
Phoenix Issue II. Is the existence of the IPR and PGR procedures beneficial to the strength of the patent system and if they are held by the Supreme Court to be unconstitutional in Oil States vs. Greene’s Energy Group then what is the impact and what if anything should be done to replace these procedures?
Phoenix Issue III. Is the current level of implementation of Section 101 supportive of having a strong patent system or has it gone too far? If it should be changed then what judicial and legislative actions regarding patent eligibility under Section 101 would best serve the patent system?
Phoenix Issue IV. How best should venue issues be determined following the Supreme Court’s recent decision in TC Heartland v. Kraft?
Phoenix Issue V. What are the economic and legal consequences (both in the U.S. and internationally) of the Supreme Court’s recent decision in Impression Products v. Lexmark, and what, if any, judicial or legislative action is needed to best address those consequences?
Phoenix Issue VI. What actions, if any, are needed to protect the U.S. patent system and U.S. patent holders in light of Brexit and ongoing developments relating to a European Unitary Patent/Unified Patent Court?
Phoenix Issue VII. To what extent is the patent system well-served by the extra-territorial enforcement of unfair competition and intellectual property laws?
Phoenix Issue VIII. What more needs to be done following the Supreme Court’s decision in Halo v. Pulse Electronics to properly determine whether a case is sufficiently egregious to warrant an award of enhanced damages? Has Halo resurrected the need to obtain an opinion of counsel, and if so, should that need be restricted to a subset of cases?
Phoenix Issue IX. Has the Supreme Court’s decision in Octane Fitness v. Icon Health adequately addressed the award of attorney fees in exceptional cases?
Phoenix Issue X. Would an exchange of an early set of Patent Damage Contentions, such as now provided for in the NDCA, aid in settling litigation and making proportionality determinations?
Phoenix Issue I. FRAND/SEP Litigation — Policy Struggles. Sorting out today’s problems.
Phoenix Issue II. The impact of recent changes to the Federal Rules of Civil Procedure? Have the changes simplified litigation? Have they impacted the cost of litigation? Curbing frivolous litigation. What is working and what is not?
Phoenix Issue III. The impact of recent decisions giving greater power to the district courts. The impact of new standards for enhanced damage awards, awards of attorneys’ fees and for review of claim construction rulings (Octane, Halo and Teva). How best to proceed and how best to protect your client? Will this encourage or discourage more litigation and/or NPE litigation?
Phoenix Issue IV. Section 101 issues. Abstract ideas? Products of nature? Diagnostic tests? Medical Procedures? Computer software (is this a dead area for protection?
Phoenix Issue V. Is there a growing anti-patent sentiment? Impact on the system? Impact on International Competition? Evaluating international litigation.
Phoenix Issue VI. Comparative Law Forum – Current Topics in Comparative and International Law.
Phoenix Issue VII. New Federal Trade Secret laws.
Phoenix Issue VIII. PTAB – Current issues. Has the process stabilized? Impact on Pharma’s molecule patents today? Use of Rule 36 affirmances in PTAB appeals? Is the Federal Circuit affirming most of the PTAB decisions? What have we learned from initial filings of PGRs?
Phoenix Issue IX. Impact of PTAB proceedings on handling of District Court litigation and how courts can/should handle multi party cases where only some of the defendants have filed IPRs. Estoppel implementation, particularly when all claims not considered or all prior art not considered?
Phoenix Issue I. To what extent is the Patent System served by judicially extending denial of patent eligibility under 35 U.S.C. § 101 beyond the concept of obviousness as enacted in 35 U.S.C. § 103? What subject matter lacks patent-eligibility that is not already denied patentability under §§ 102, 103, 112? How broadly should the § 101 eligibility standard be applied; e.g., in the biotech area, for medical diagnostics, and for all machines controlled by any computer program?
Phoenix Issue II. Has the Patent System been well served by judicial pronouncements of patent preemption? (Cf. Bilski, Mayo, Alice denying patent-eligibility on the basis of “preemption” of the basic building blocks of science.) Should patents preempt experimentation on, and not with, the patented invention? (Deuterium Corp. v. U.S., 21 Cl. Ct. 132). Should the “all elements” rule that excludes infringement of a combination claim obviate the “preemption” concern where an otherwise ineligible element is paired in a combination claim that together provides an “inventive” (nonobvious) advance?
Phoenix Issue III. Is innovation well served by the limitation on international patent exhaustion reflected in the result in Jazz Photo? (Cf. Lexmark on the way to the Supreme Court.) To what extent do notions of copyright exhaustion shed light on issues of patent exhaustion?
Phoenix Issue IV. What policies should the USPTO adopt to streamline and expedite prosecution; e.g., placing limits on RCEs, creating greater certainty in making actions final, and resurrecting the doctrine of undue multiplicity?
Phoenix Issue V. What changes are necessary to constructively better implement the AIA?
Phoenix Issue VI. With the new requirement in the Federal Rules to address proportionality for determining the scope of discovery, how should the District Courts proceed in making the determination?